MIM
LNAI

MetLife Investment Management’s Lunai Bioworks LNAI Stock Holding History

MetLife Investment Management’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-943
Closed -$63K – 2820
2024
Q4 		$63K Buy
+943
New +$62.6K ﹤0.01% 2719

Other funds holding LNAI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's LNAI Position: Q1 2025 in Review

MetLife Investment Management sold out of Lunai Bioworks (LNAI) in Q1 2025, closing a stake of 943 shares — an estimated $63K sold.

MetLife Investment Management first reported a position in LNAI in Q4 2024 and held it in 1 quarter. The position peaked at $63K in Q4 2024. 60 funds tracked by Wall St. Rank hold LNAI as of Q1 2025.

  • MetLife Investment Management reported no remaining Lunai Bioworks position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 943 Lunai Bioworks shares in Q1 2025, an estimated $63K.
  • MetLife Investment Management first reported a position in Lunai Bioworks in Q4 2024 and held it in 1 quarter.
  • MetLife Investment Management's Lunai Bioworks position peaked at $63K in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.